The purpose of the Administrative Core is to establish the research agenda for the ADRC and to insure the optimal utilization of Center resources by maximizing institutional strengths in the service of broadening knowledge about diagnosis, management, treatment, and prevention of AD and other dementias through basic and applied research.
The specific aims are to 1) Provide the leadership to facilitate the overall research goals of the ADRC. 2) Coordinate and integrate ADRC activities ensuring that the Cores meet the needs of the Projects and that the Projects are utilizing the Cores. 3)Foster growth of new research initiatives and recruit new researchers through the pilot program and through other institutional resources. 4) Ensure future growth for the ADRC. This includes maintaining a proper balance of faculty and staff renewal in order to insure that our clinical and other core operations are accomplished and also setting future directions and optimizing resources available to Insure that our research efforts grow. 5) Facilitate communication: (a) with NACC to insure timely transmission of data sets;(b) with other ADCs to maximize collaboration;and (c) with NIA program staff including coordination with NIA on media coverage and dissemination of Important findings. 6) Facilitate interaction with the Alzheimer's Disease Cooperative Study and other clinical trial organizations. 7) Provide administrative oversight. This includes developing and maintaining budgets and ensuring that funds are utilized to conduct and enhance Core and scientific activities. The Core functions are managed through routine meetings and reporting and auditing routines. The leadership of the Core is advised by both internal and external advisory boards.

Public Health Relevance

The Administration Core functions to insure commitment to cutting edge science that will lead to early diagnosis, better treatments, and, ultimately, prevention of Alzheimer's disease and other cognitive disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005138-27
Application #
8440470
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4)
Project Start
1997-05-01
Project End
2015-03-31
Budget Start
2011-04-01
Budget End
2012-03-31
Support Year
27
Fiscal Year
2011
Total Cost
$264,968
Indirect Cost
Name
Icahn School of Medicine at Mount Sinai
Department
Type
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Ki?emet-Piska?, Spomenka; Babi? Leko, Mirjana; Blažekovi?, Antonela et al. (2018) Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer's disease and vascular dementia. CNS Neurosci Ther 24:734-740
Soleimani, Laili; Ravona-Springer, Ramit; Heymann, Anthony et al. (2018) Depression is more strongly associated with cognition in elderly women than men with type 2 diabetes. Int Psychogeriatr :1-5
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Audrain, Mickael; Haure-Mirande, Jean-Vianney; Wang, Minghui et al. (2018) Integrative approach to sporadic Alzheimer's disease: deficiency of TYROBP in a tauopathy mouse model reduces C1q and normalizes clinical phenotype while increasing spread and state of phosphorylation of tau. Mol Psychiatry :
Boban, Mirta; Babi? Leko, Mirjana; Miški?, Terezija et al. (2018) Human neuroblastoma SH-SY5Y cells treated with okadaic acid express phosphorylated high molecular weight tau-immunoreactive protein species. J Neurosci Methods :
Zhu, Carolyn W; Grossman, Hillel; Neugroschl, Judith et al. (2018) A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer's disease: A pilot study. Alzheimers Dement (N Y) 4:609-616
Qian, Winnie; Fischer, Corinne E; Schweizer, Tom A et al. (2018) Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease. Curr Alzheimer Res 15:187-194
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021
Gallagher, Damien; Kiss, Alex; Lanctot, Krista et al. (2018) Depression and Risk of Alzheimer Dementia: A Longitudinal Analysis to Determine Predictors of Increased Risk among Older Adults with Depression. Am J Geriatr Psychiatry 26:819-827
Silverman, Jeremy M; Schmeidler, James (2018) Outcome age-based prediction of successful cognitive aging by total cholesterol. Alzheimers Dement 14:952-960

Showing the most recent 10 out of 555 publications